Related Experiment Video
Updated: Feb 15, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder
Ahmed T Ahmed1, Richard Weinshilboum2, Mark A Frye1
1Department of Psychiatry and Psychology and Mayo Clinic Depression Center, Rochester, Minnesota, USA.
Abstract:
Antidepressants have reduced the symptom burden for many Major Depressive Disorder (MDD) patients, but drug-related side effects and treatment resistance continue to present major challenges. Pharmacogenomics represents one approach to enhance antidepressant efficacy and avoid adverse reactions, but concerns remain with regard to the overall "value equation," and several barriers must be overcome to achieve the full potential of MDD pharmacogenomics.
Related Concept Videos
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depressive Disorders: MDD and Dysthymia
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Pharmacogenetics and Pharmacogenomics: Overview
Benefits of Self-Esteem
Long-term Depression

